

## Summary of risk management plan for Azacitidine Accord 25 mg/mL powder for suspension for injection (Azacitidine)

This is a summary of the risk management plan (RMP) for Azacitidine Accord 25 mg/mL powder for suspension for injection. The RMP details important risks of Azacitidine Accord 25 mg/mL powder for suspension for injection, how these risks can be minimised, and how more information will be obtained about Azacitidine Accord 25 mg/mL powder for suspension for injection's risks and uncertainties (missing information).

Azacitidine Accord 25 mg/mL powder for suspension for injection's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Azacitidine Accord 25 mg/mL powder for suspension for injection should be used.

This summary of the RMP for Azacitidine Accord 25 mg/mL powder for suspension for injection should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Azacitidine Accord 25 mg/mL powder for suspension for injection's RMP.

### **I. The medicine and what it is used for**

Azacitidine Accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

- Intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- Chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,
- Acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
- AML with >30% marrow blasts according to the WHO classification.

It contains azacitidine as the active substance and it is given subcutaneously.

Further information about the evaluation of Azacitidine Accord 25 mg/mL powder for suspension for injection's benefits can be found in Azacitidine Accord 25 mg/mL powder for suspension for injection's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage.

<https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord>

## **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Azacitidine Accord 25 mg/mL powder for suspension for injection together with measures to minimise such risks and the proposed studies for learning more about Azacitidine Accord 25 mg/mL powder for suspension for injection's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

### **II.A List of important risks and missing information**

Important risks of Azacitidine Accord 25 mg/mL powder for suspension for injection are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Azacitidine Accord 25 mg/mL powder for suspension for injection. Potential risks are concerns

for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Important identified risks	<ul style="list-style-type: none"><li>• Haemorrhagic events</li><li>• Infections</li></ul>
Important potential risks	<ul style="list-style-type: none"><li>• None</li></ul>
Missing information	<ul style="list-style-type: none"><li>• None</li></ul>

## **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

## **II.C Post-authorisation development plan**

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Azacitidine Accord 25 mg/mL powder for suspension for injection.

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Azacitidine Accord 25 mg/mL powder for suspension for injection.